SE0202463D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0202463D0
SE0202463D0 SE0202463A SE0202463A SE0202463D0 SE 0202463 D0 SE0202463 D0 SE 0202463D0 SE 0202463 A SE0202463 A SE 0202463A SE 0202463 A SE0202463 A SE 0202463A SE 0202463 D0 SE0202463 D0 SE 0202463D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
compounds
inhibitors
therapy
Prior art date
Application number
SE0202463A
Other languages
English (en)
Inventor
Thomas Brimert
Tero Linnanen
Peter Nielsen
Peter Sjoe
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0202463A priority Critical patent/SE0202463D0/sv
Publication of SE0202463D0 publication Critical patent/SE0202463D0/sv
Priority to AU2003248588A priority patent/AU2003248588A1/en
Priority to JP2004528997A priority patent/JP2006500362A/ja
Priority to AU2003253532A priority patent/AU2003253532A1/en
Priority to PCT/SE2003/001272 priority patent/WO2004016609A1/en
Priority to US10/524,626 priority patent/US20050261331A1/en
Priority to EP03788209A priority patent/EP1539757A1/en
Priority to US10/524,361 priority patent/US20050215582A1/en
Priority to PCT/SE2003/001275 priority patent/WO2004016610A1/en
Priority to JP2004529000A priority patent/JP2006500363A/ja
Priority to EP03788212A priority patent/EP1539758A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SE0202463A 2002-08-14 2002-08-14 Novel compounds SE0202463D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE0202463A SE0202463D0 (sv) 2002-08-14 2002-08-14 Novel compounds
EP03788212A EP1539758A1 (en) 2002-08-14 2003-08-13 Substituted pyrrolopyridines
PCT/SE2003/001272 WO2004016609A1 (en) 2002-08-14 2003-08-13 Substituted pyrrolopyridines
JP2004528997A JP2006500362A (ja) 2002-08-14 2003-08-13 置換ピロロピリジン類
AU2003253532A AU2003253532A1 (en) 2002-08-14 2003-08-13 Substituted pyrrolopyridines
AU2003248588A AU2003248588A1 (en) 2002-08-14 2003-08-13 Substituted pyrrolopyridines
US10/524,626 US20050261331A1 (en) 2002-08-14 2003-08-13 Substituted pyrrolopyridines
EP03788209A EP1539757A1 (en) 2002-08-14 2003-08-13 Substituted pyrrolopyridines
US10/524,361 US20050215582A1 (en) 2002-08-14 2003-08-13 Substituted pyrrolopyridines
PCT/SE2003/001275 WO2004016610A1 (en) 2002-08-14 2003-08-13 Substituted pyrrolopyridines
JP2004529000A JP2006500363A (ja) 2002-08-14 2003-08-13 置換ピロロピリジン

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0202463A SE0202463D0 (sv) 2002-08-14 2002-08-14 Novel compounds

Publications (1)

Publication Number Publication Date
SE0202463D0 true SE0202463D0 (sv) 2002-08-14

Family

ID=20288751

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0202463A SE0202463D0 (sv) 2002-08-14 2002-08-14 Novel compounds

Country Status (6)

Country Link
US (2) US20050215582A1 (sv)
EP (2) EP1539758A1 (sv)
JP (2) JP2006500363A (sv)
AU (2) AU2003253532A1 (sv)
SE (1) SE0202463D0 (sv)
WO (2) WO2004016610A1 (sv)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082868A1 (en) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
US7432375B2 (en) * 2003-03-06 2008-10-07 Eisai R & D Management Co., Ltd. JNK inhibitors
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
EP1628975A2 (en) 2003-05-16 2006-03-01 Eisai Co., Ltd. Jnk inhibitors
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
PL2332940T3 (pl) 2004-03-30 2013-03-29 Vertex Pharma Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
KR20070002081A (ko) 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Ｒｏｃｋ 및 기타 단백질 키나아제의 억제제로서 유용한아자인돌
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
US20060058339A1 (en) * 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
EP1765819B1 (en) * 2004-06-30 2014-03-12 Vertex Pharmaceuticals Inc. Azaindoles useful as inhibitors of protein kinases
MX2007000092A (es) * 2004-06-30 2007-03-07 Vertex Pharma Azaindoles utiles como inhibidores de proteinas cinasas.
DE102004060659A1 (de) 2004-12-15 2006-07-06 Lanxess Deutschland Gmbh Neue substituierte 1H-Pyrrolo[2,3-b]pyridine und deren Herstellung
RU2423351C2 (ru) 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
ATE524467T1 (de) 2005-04-25 2011-09-15 Merck Patent Gmbh Neuartige aza-heterozyklen als kinase-inhibitoren
WO2006124863A2 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
KR20080027775A (ko) 2005-05-17 2008-03-28 플렉시콘, 인코퍼레이티드 피롤(２,３-ｂ)피리딘 유도체 단백질 키나제 억제제
CN102603581B (zh) * 2005-06-22 2015-06-24 普莱希科公司 作为蛋白质激酶抑制剂的吡咯并[2,3-b]吡啶衍生物
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
EA017618B1 (ru) * 2005-09-21 2013-01-30 Декод Дженетикс Ехф Биарилзамещенные гетероциклические ингибиторы lta4h для лечения воспаления
WO2007058832A2 (en) * 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
BRPI0706537A2 (pt) 2006-01-17 2011-03-29 Vertex Pharma azaindóis úteis como inibidores de janus cinases
CA2858520A1 (en) 2006-05-18 2007-11-29 Pharmacyclics Inc. Intracellular kinase inhibitors
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
EP2815750A1 (en) 2006-12-21 2014-12-24 Vertex Pharmaceuticals Incorporated 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors
WO2008080001A2 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US20110184026A1 (en) * 2008-06-19 2011-07-28 Boger Dale L C4-substituted alpha-keto oxazoles
WO2010005572A2 (en) * 2008-07-09 2010-01-14 The Scripps Research Institute Alpha-keto heterocycles as faah inhibitors
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
CR20170089A (es) 2009-04-03 2017-07-17 Plexxikon Inc Composiciones del acido propano-1--sulfonico {3-[5-(4-cloro-fenil)-1h-pirrolo [2,3-b] piridina-3-carbonil] -2,4-difluoro-fenil}-amida y el uso de las mismas
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
KR101907535B1 (ko) * 2009-10-02 2018-10-15 아벡신 에이에스 소염제 2-옥소티아졸 및 2-옥소옥사졸
CA2779785C (en) * 2009-11-04 2017-09-12 Nerviano Medical Sciences S.R.L. Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1h-pyrrole-3-carboxamides
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2011057960A1 (en) * 2009-11-11 2011-05-19 Nerviano Medical Sciences S.R.L. Crystalline cdc7 inhibitor salts
KR20140014110A (ko) 2010-12-16 2014-02-05 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
MA34948B1 (fr) 2011-02-07 2014-03-01 Plexxikon Inc Composes et procedes de modulation de kinase, et leurs indications
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9096598B2 (en) 2011-10-03 2015-08-04 Merck Sharp & Dohme Corp. Azaindoles as Janus kinase inhibitors
WO2013153539A1 (en) 2012-04-13 2013-10-17 Glenmark Pharmaceuticals S.A. Tricyclic compounds as tec kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
MD20140130A2 (ro) 2012-06-29 2015-04-30 Pfizer Inc. 4-(amino-substituite)-7H-pirolo[2,3-d]pirimidine noi ca inhibitori de LRRK2
WO2014024119A1 (en) * 2012-08-06 2014-02-13 Glenmark Pharmaceuticals S.A. Heterocyclic amides as itk inhibitors
CN103772380A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN103804381A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
WO2014118195A1 (en) 2013-01-29 2014-08-07 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
US9795604B2 (en) 2013-10-25 2017-10-24 Pharmacyclics Llc Methods of treating and preventing graft versus host disease
JP6615755B2 (ja) 2013-11-13 2019-12-04 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルスの複製の阻害剤
SI3068782T1 (sl) 2013-11-13 2018-10-30 Vertex Pharmaceuticals Incorporated Postopki za pripravo inhibitorjev v replikacije virusov gripe
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
AR103232A1 (es) * 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
BR112018003836A2 (pt) 2015-08-31 2018-12-04 Pharmacyclics Llc combinações de inibidor de btk para tratar mieloma múltiplo
AU2016322813B2 (en) 2015-09-14 2021-04-01 Pfizer Inc. Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
WO2018085731A2 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
MX2019008458A (es) 2017-01-17 2019-12-02 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos.
CN108084076A (zh) * 2017-12-21 2018-05-29 苏州艾缇克药物化学有限公司 一种5-溴-7-氮杂吲哚的合成方法
CA3098497A1 (en) 2018-05-03 2019-11-07 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
WO2023110843A1 (en) * 2021-12-15 2023-06-22 Almirall, S.A. Heterobicyclic derivatives as itk inhibitors
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69728688T2 (de) * 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
US20050261331A1 (en) 2005-11-24
WO2004016609A1 (en) 2004-02-26
AU2003248588A1 (en) 2004-03-03
EP1539757A1 (en) 2005-06-15
EP1539758A1 (en) 2005-06-15
JP2006500362A (ja) 2006-01-05
AU2003253532A1 (en) 2004-03-03
US20050215582A1 (en) 2005-09-29
JP2006500363A (ja) 2006-01-05
WO2004016610A1 (en) 2004-02-26

Similar Documents

Publication Publication Date Title
SE0202463D0 (sv) Novel compounds
HK1080470A1 (en) Heterocyclic compounds
HK1089163A1 (en) Quinoxaline derivatives as neutrophil elastase inhibitors and their use
SE0302487D0 (sv) Novel compounds
HK1079522A1 (en) Thienyl compounds
MY132106A (en) New pyridazin-3(2h)-one derivatives
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
DE60334536D1 (de) Furylverbindungen
SE0302323D0 (sv) Novel compounds
GB0112348D0 (en) Compounds
SE0402762D0 (sv) Indazole sulphonamide derivatives
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
SE0302573D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
SE0301701D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0302756D0 (sv) Novel Compounds
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
GB0308201D0 (en) Novel compounds
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0202461D0 (sv) Novel compounds
SE9904676D0 (sv) Novel compounds
SE9901901D0 (sv) Compounds
SE0403117D0 (sv) New compounds 1
SE0400285D0 (sv) Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof